Seacross Pharmaceutical Co Ltd | Sichuan Huiyu Pharmaceuticals Co., Ltd. - R&D Site

The R&D Center plays a pivotal role in supporting the development of both APIs and finished dosage forms. This includes oral solids, lyophilized powders, pre-filled syringes, injection pens, and especially complex injectable formulations such as long-acting implants, microspheres, nanocrystals/nanoparticles, liposomes, albumin-bound drugs, and injectable gels.

The R&D Center is built upon three integrated technology platforms:

Generic Consistency Evaluation Platform

A scientific, comprehensive, and efficient system for injection consistency evaluation, encompassing project management, experimental research, technology transfer, and both domestic and international registration strategies.

API Quality Control and Production Technology Platform

This platform focuses on chiral drug development, crystallization and purification techniques, with strong expertise in oncology APIs, tumor adjuvant therapies, and contrast agents. It also extends to APIs in cardiovascular, anti-infective, and antibiotic areas.

Complex Formulation Process Control Technology Platform

• Equipped to support advanced formulation development, this platform includes:
• Polymer excipient preparation and purification
• Continuous manufacturing for nanoscale formulations
• Twin-screw hot melt extrusion
• Online high-shear dispersion
• Suspension-injection flow cell technology for dissolution control
• Micelle-free drug quality control methods

Together, these platforms enable us to accelerate development timelines, ensure regulatory compliance, and deliver high-quality, complex pharmaceutical products to global markets.